PK/PD model‐informed dose selection for oncology phase I expansion: Case study based on PF‐06939999, a PRMT5 inhibitor

The optimal dose for targeted oncology therapeutics is often not the maximum tolerated dose. Pharmacokinetic/pharmacodynamic (PK/PD) modeling can be an effective tool to integrate clinical data to help identify the optimal dose. This case study shows the utility of population PK/PD modeling in selec...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Cen, Liao, Kai H., Li, Meng, Wang, I‐Ming, Shaik, Naveed, Yin, Donghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681508/
https://www.ncbi.nlm.nih.gov/pubmed/36394153
http://dx.doi.org/10.1002/psp4.12882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681508/
https://www.ncbi.nlm.nih.gov/pubmed/36394153
http://dx.doi.org/10.1002/psp4.12882

Ejemplares similares